Abstract
Choosing Wisely is an initiative by the American Board of Internal Medicine (ABIM) “that seeks to advance a national dialogue on avoiding unnecessary medical tests, treatments and procedures” (2). In line with the initiative, Borges and cols. published an interesting review in this edition of the Archives of Endocrinology and Metabolism with the aim of rationalizing statin treatment to reduce side effects and improve adherence (3). However, how simple is it to choose statins wisely for individual patients? Should the decision be based on evidence, efficacy, or safety?